58578-45-3

Basic information

• Product Name: 4-oxo-2S-[[(phenymethyoxy)carbonyl]amino]-butyric acid phenymethyl ester
• Synonyms: 4-oxo-2S-[[(phenymethyoxy)carbonyl]amino]-butyric acid phenymethyl ester;(S)-4-Oxo-2-[[(phenylmethoxy)carbonyl]amino]butanoic acid phenylmethyl ester;Benzyl 4-oxo-2-(S)-[[(phenylmethoxy)carbonyl]amino]butanoate;S)-benzyl 2-(benzyloxycarbonylaMino)-4-oxobutanoate;PhenylMethyl 4-oxo-2(S)-[[(plenylMethoxy)carbonyl]aMino]butanoate
• CAS NO: 58578-45-3
• Molecular Formula: C₁₉H₁₉NO₅
• Molecular Weight: 341.36
• Mol File: 58578-45-3.mol

Chemical Properties

• Melting Point: 80.5-82 ºC
• Boiling Point: 534.1°C at 760 mmHg
• Flash Point: 276.8°C
• Appearance: /
• Density: 1.223
• Vapor Pressure: 1.74E-11mmHg at 25°C
• Refractive Index: 1.564
• PKA: 10.47±0.46(Predicted)
• CAS DataBase Reference: 4-oxo-2S-[[(phenymethyoxy)carbonyl]amino]-butyric acid phenymethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-oxo-2S-[[(phenymethyoxy)carbonyl]amino]-butyric acid phenymethyl ester(58578-45-3)
• EPA Substance Registry System: 4-oxo-2S-[[(phenymethyoxy)carbonyl]amino]-butyric acid phenymethyl ester(58578-45-3)

Safety Data

• Hazardous Substances Data: 58578-45-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-oxo-2S-[[(phenylmethoxy)carbonyl]amino]-butyric acid phenylmethyl ester is used as a potential anti-cancer agent for its ability to exhibit anti-tumor effects. 4-oxo-2S-[[(phenymethyoxy)carbonyl]amino]-butyric acid phenymethyl ester's structure, including the phenylmethyl ester group, may contribute to its efficacy in penetrating cell membranes and targeting specific tissues, making it a candidate for further research and development in oncology.
Used in Drug Development Research:
In the field of drug development, 4-oxo-2S-[[(phenylmethoxy)carbonyl]amino]-butyric acid phenylmethyl ester serves as a subject of investigation for its potential pharmacological properties. Researchers are exploring its mechanisms of action and how it may be utilized in the creation of novel therapeutics for cancer treatment, taking advantage of its butyric acid derivative nature and phenylmethyl ester group for enhanced bioactivity and selectivity.

InChI:InChI=1/C19H19NO5/c21-12-11-17(18(22)24-13-15-7-3-1-4-8-15)20-19(23)25-14-16-9-5-2-6-10-16/h1-10,12,17H,11,13-14H2,(H,20,23)

Upstream product

• 58578-44-2 benzyl L-2-<(carbobenzxyloxy)amino>-4-hydroxybutyrate 
• 58578-43-1 (S)-2-benzyloxycarbonylamino-4-hydroxybutyric acid dicyclohexylamine salt 
• 100-39-0 benzyl bromide 
• 35677-89-5 benzyl (3S)-2-oxotetrahydro-3-furanylcarbamate 
• 4779-31-1 Z-Asp-OBn 
• 35677-88-4 N-benzyloxycarbonyl-(L)-homoserine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 58578-46-4 (S)-2-Benzyloxycarbonylamino-4,4-dimethoxy-butyric acid benzyl ester 
• 109429-17-6 (2S,5R,7S)-1-aza-7-benzyloxycarbonylamino-8-oxo-4-thiabicyclo<3.3.0>octane-2-carboxylic acid methyl ester 
• 125075-17-4 (2R,5S,7R)-1-aza-7-benzyloxycarbonylamino-8-oxo-4-thiabicyclo<3.3.0>octane-2-carboxylic acid methyl ester 
• 109317-07-9 (2R,5S,7S)-1-aza-7-benzyloxycarbonylamino-8-oxo-4-thiabicyclo<3.3.0>octane-2-carboxylic acid methyl ester 
• 109317-05-7 (2ξ,4R,2'S)-<2'-(benzyloxycarbonylaminopropanoic acid benzyl ester)>-3-aza-4-(methoxycarbonyl)tetrahydrothiophene 
• 109317-05-7 (2Ξ,4S,2'S)-<2'-(benzyloxycarbonylaminopropanoic acid benzyl ester)>-3-aza-4-(methoxycarbonyl)tetrahydrothiophene 
• 125075-16-3 (2S,5R,7R)-1-aza-7-benzyloxycarbonylamino-8-oxo-4-thiabicyclo<3.3.0>octane-2-carboxylic acid methyl ester 
• 396080-48-1 C₂₈H₃₁N₃O₆ 
• 754987-62-7 (2S)-2-benzyloxycarbonylamino-4-oxo-hexanedioic acid 1-benzyl ester 6-ethyl ester 
• 76-05-1 trifluoroacetic acid 

Relevant articles and documents

Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice

Plasmodium falciparum proteasome (Pf20S) inhibitors are active against Plasmodium at multiple stages—erythrocytic, gametocyte, liver, and gamete activation stages—indicating that selective Pf20S inhibitors possess the potential to be therapeutic, prophyla

PROCESS FOR THE PREPARATION OF N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE

The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employ

MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Concise Synthesis of Enantiomerically Pure (1′S,2′R)-and (1′R,2′S)-2S-Amino-3-(2′-aminomethyl-cyclopropyl)propionic Acid: Two E-Diastereoisomers of 4,5-Methano-l-lysine

A concise synthesis of both E-isomers of 2S-amino-3-(2′-aminomethyl- cyclopropyl)propionic acid, new methano-l-lysines, is described. The synthetic route includes nine steps from l-methionine, with a key step involving the cyclopropanation of an intermediate E-allylic alcohol. The resultant hydroxymethylcyclopropanes were readily separated and converted into the title α-amino acids. The stereochemistry around the cyclopropane rings was deduced by conducting the cyclopropanation in the presence of N,N,N′,N′-tetramethyl-d-tartaric acid diamide butylboronate, a chiral controller which is known to favour the production of S-hydroxymethyl cyclopropanes from allylic alcohols.

A facile transformation of amino acids to functionalized coumarins

The synthesis of novel chiral coumarins functionalized with proteinogenic amino acid side chains via N-protected γ-amino-β-keto esters and their incorporation into the cell permeable HIV-1 TAT peptide through the modified solid phase peptide synthesis are

Synthesis of a serine-based neuraminic acid C-glycoside

Cell-surface carbohydrates are classified by the nature of their linkages to the protein as either N-linked or O-linked. O- and N-glycans are involved in a number of important biological functions. These activities can be lost on glycoprotein catabolism w

4-N-Hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase

Analogues of glutamic acid were synthesized and evaluated for their inhibitory activity toward glutamine synthetase (EC 6.3.1.2; GS). The title compound, 4-N-hydroxy-L-2,4-diaminobutyric acid (NH-DABA), showed a potent inhibitory activity against GS from